COPD — Emphysema and Chronic Bronchitis

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable airway disease characterized by persistent airflow limitation resulting from abnormal inflammatory response to noxious particles or gases. The disease encompasses two major pathological entities—emphysema (permanent destruction of alveolar walls without significant fibrosis) and chronic bronchitis (chronic productive cough for ≥3 months in each of 2 consecutive years)—though most patients exhibit features of both. COPD represents the fourth leading cause of death globally with prevalence increasing in developing nations, affecting approximately 10-15% of adults over age 40 in developed countries, with male predominance historically narrowing as female smoking rates rise. The disease is responsible for substantial morbidity, mortality, and healthcare costs, making recognition and management essential for clinical practice. Understanding the distinct pathophysiological mechanisms underlying emphysema versus chronic bronchitis, along with current evidence-based management strategies, is critical for board examinations and patient care.

COPD results from complex interactions between environmental exposures (primarily cigarette smoke), genetic predisposition, and dysregulated inflammatory responses leading to progressive airway obstruction and parenchymal destruction.

Cigarette smoke and environmental pollutants generate reactive oxygen species (ROS) including superoxide anion and hydroxyl radicals, overwhelming endogenous antioxidant systems (superoxide dismutase, catalase, glutathione). This oxidative imbalance activates NF-κB and MAPK pathways in airway and alveolar macrophages, triggering release of pro-inflammatory cytokines including TNF-α, IL-6, IL-8, and GM-CSF. These chemokines recruit neutrophils, eosinophils, and CD8+ T lymphocytes to the lung parenchyma. Neutrophil elastase and other proteases degrade extracellular matrix proteins (elastin, collagen) unchecked by depleted antiprotease reserves, culminating in progressive alveolar destruction characteristic of emphysema. Additionally, oxidative stress drives mucin production and impairs ciliary function, contributing to chronic bronchitis phenotype.

In emphysema, destruction of alveolar walls eliminates the elastic scaffolding necessary for passive lung recoil. Loss of elastic recoil increases the work of expiration, promoting air trapping and dynamic hyperinflation. With breathing, intraluminal pressure fails to exceed atmospheric pressure during expiration—"expiratory flow limitation"—preventing complete lung emptying. Consequently, functional residual capacity (FRC) increases dramatically, flattening the diaphragm and shifting it to a mechanically disadvantaged position on the length-tension curve. This compromises inspiratory muscle efficiency and increases oxygen consumption by respiratory muscles, exacerbating dyspnea. Destruction of alveolar capillary beds simultaneously reduces the surface area available for gas exchange, impairing both oxygenation and CO₂ elimination.

Chronic inflammation induces pathological remodeling of small airways (<2 mm internal diameter). Goblet cell hyperplasia increases mucus production; smooth muscle hypertrophy and increased tone narrow the airway lumen; and fibrosis of the airway wall reduces compliance. Inflammatory exudates and mucus plugging further compromise airway patency. Small airways lack cartilaginous support and collapse readily during expiration when transmural pressure becomes negative, exacerbating air trapping. These changes are more prominent in the chronic bronchitis phenotype but coexist with emphysematous changes in most COPD patients.

The protease-antiprotease imbalance is central to COPD pathogenesis. Normal lung tissue is protected by α₁-antitrypsin (AAT), a serum glycoprotein that inhibits neutrophil elastase. Cigarette smoke directly oxidizes methionine residues in AAT's reactive site, rendering it inactive. Smoke also increases protease-producing cells and their activity while reducing systemic AAT levels through oxidative inactivation and increased consumption. Genetic AAT deficiency (phenotypes PiZZ, PiMZ) markedly accelerates emphysema development, particularly in apical-basilar distribution. Even heterozygous carriers (PiMZ) show modestly increased risk with smoking.

COPD is characterized by impaired selective autophagy in macrophages and other cells, preventing efficient clearance of damaged organelles and intracellular pathogens. Cigarette smoke suppresses PINK1/Parkin-mediated mitophagy, leading to accumulation of dysfunctional mitochondria, perpetuating ROS generation and inflammation. Epithelial cell apoptosis, triggered by oxidative stress and cigarette smoke constituents, paradoxically fails to trigger appropriate resolution mechanisms, instead perpetuating inflammation through enhanced danger-associated molecular pattern (DAMP) release.

COPD extends beyond the lung as a systemic inflammatory condition. Systemic levels of C-reactive protein, TNF-α, IL-6, and fibrinogen are elevated even in stable disease, correlating with muscle wasting, cardiovascular disease, and metabolic dysfunction. Systemic inflammation contributes to increased risk of myocardial infarction, stroke, osteoporosis, skeletal muscle wasting (cachexia), depression, and diabetes in COPD patients.

Cigarette smoking is responsible for approximately 85-90% of COPD cases in developed nations. Risk is dose-dependent, related to pack-years (number of packs per day × years smoked). Typically, COPD develops after 20+ pack-years, though highly susceptible individuals may develop disease with fewer pack-years. The Framingham study demonstrated that 15-20% of smokers develop COPD, indicating individual genetic predisposition modulates susceptibility. Secondhand smoke exposure increases COPD risk in never-smokers, though to lesser degree than active smoking. The accelerated decline in FEV₁ in smokers (~60 mL/year) compared to non-smokers (~30 mL/year) demonstrates the dose-response relationship.

Genetic AAT deficiency accounts for 1-3% of COPD cases in developed countries but represents an important secondary cause and indication for targeted screening. Severe AAT deficiency (serum levels <57 μmol/L or <11 μM, phenotype PiZZ) confers >1000-fold increased risk for early-onset emphysema (age 30-40 years), characteristically affecting basilar and posterior lung zones (opposite of smoking-predominant upper lobe pattern). Heterozygous carriers (PiMZ) have intermediate risk. All patients with COPD age <45 years or with basilar-predominant emphysema should undergo AAT level testing (pi function test); those with deficiency warrant discussion of AAT replacement therapy and genetic counseling.

Workplace exposures account for 5-20% of COPD cases. High-risk occupations include coal mining (coal worker's pneumoconiosis), metal welding (metal fume fever, cadmium exposure), grain handling (organic dust), and construction (silica, asbestos). Outdoor air pollution (particulate matter, nitrogen dioxide, ozone) accelerates FEV₁ decline. Indoor biomass fuel exposure in developing nations is an increasingly recognized major risk factor, particularly among women in regions with poor ventilation during cooking.

Beyond AAT deficiency, genome-wide association studies (GWAS) have identified numerous loci associated with COPD susceptibility, including genes regulating inflammation (TNF-α, IL-6), oxidative stress (SOD3, catalase), protease activity (neutrophil elastase), and apoptosis. The CHRNA3 locus near nicotinic acetylcholine receptor genes confers increased smoking addiction and COPD risk. These genetic factors explain why only 15-20% of smokers develop clinically significant airflow obstruction despite similar smoking exposures.

Recurrent lower respiratory infections, particularly viral (influenza, rhinovirus, adenovirus, respiratory syncytial virus) and bacterial (Haemophilus influenzae, Streptococcus pneumoniae), accelerate airway remodeling and inflammation. Childhood respiratory infections predict COPD development independent of adult smoking exposure, suggesting developmental programming of airway disease. The "Dutch hypothesis" suggests chronic airway hyperresponsiveness predisposes to both asthma and COPD.

Poor lung function growth in childhood and young adulthood (due to lower socioeconomic status, infections, secondhand smoke exposure, asthma) increases COPD risk in later life. The Framingham study demonstrated that individuals with FEV₁ in the lowest quartile at age 25 had substantially higher COPD incidence despite smoking cessation.

Progressive, often exertional dyspnea is the hallmark symptom, reflecting the combination of increased work of breathing (due to airflow limitation and air trapping), reduced inspiratory muscle efficiency (flattened diaphragm), and impaired gas exchange. Dyspnea often correlates poorly with objective measures of airflow obstruction (FEV₁), suggesting significant contribution from dynamic hyperinflation, respiratory muscle weakness, and psychological factors. Early dyspnea manifests with exertion (NYHA-style classification); advanced disease causes dyspnea at rest.

Persistent, often productive cough lasting ≥3 months per year is more typical of the chronic bronchitis phenotype, reflecting mucus hyperproduction from goblet cell metaplasia and impaired mucociliary clearance. The cough is typically worse in morning as patients mobilize secretions after sleeping. Most productive cough occurs in bronchitic phenotype, though emphysema-predominant patients may have dry cough. Hemoptysis should prompt investigation for alternative diagnoses (lung cancer, bronchiectasis, infection) rather than attributing to COPD alone.

Chronic sputum production, typically mucoid and clear to yellowish in stable disease, becomes purulent during exacerbations suggesting bacterial superinfection. Sputum volume correlates with the degree of small airway inflammation and remodeling.

In advanced COPD, hyperinflation causes increased anteroposterior chest diameter producing the characteristic "barrel chest" appearance. Patients often unconsciously adopt pursed-lip breathing, which maintains positive airway pressure during expiration, preventing small airway collapse and reducing air trapping—this is essentially an autodidactic positive expiratory pressure (PEP) maneuver.

Use of scalene and sternocleidomastoid muscles during quiet breathing indicates severe airflow obstruction and increased respiratory muscle burden. Abdominal paradox (inward abdominal wall movement during inspiration) reflects severe diaphragmatic dysfunction.

Auscultation reveals globally diminished breath sounds reflecting emphysematous loss of lung parenchyma and reduced airflow. Expiration is markedly prolonged (often >6 seconds) due to flow limitation. Wheezes may be present, particularly during exacerbations, though absence of wheezes does not exclude COPD.

Peripheral cyanosis (blue discoloration of lips and extremities) indicates desaturation. Central cyanosis (bluish tongue) suggests severe hypoxemia. Advanced COPD with chronic hypoxemia predisposes to pulmonary hypertension and right ventricular hypertrophy (cor pulmonale), manifesting as elevated jugular venous pressure, right ventricular heave, hepatomegaly (often pulsatile with tricuspid regurgitation), and peripheral edema.

Patients with predominantly emphysematous pathology present with prominent dyspnea, use of accessory muscles, and pursed-lip breathing. They maintain relatively normal oxygen saturation until late disease through increased respiratory rate and minute ventilation, resulting in pink skin appearance. Chest imaging shows marked hyperinflation with flattened diaphragms. These patients typically have lower sputum production and lower incidence of exacerbations.

Patients with predominant chronic bronchitis phenotype present earlier with cough and sputum production, often with significant hypoxemia and hypercapnia even with modest airflow obstruction. They may appear cyanotic and bloated (fluid retention from cor pulmonale). Small airway remodeling and mucus plugging cause greater ventilation-perfusion (V/Q) mismatch than emphysema-predominant disease. These patients are more prone to acute exacerbations, bacterial infections, and respiratory failure.

Approximately 15-20% of COPD patients have significant features of asthma including reversible airflow obstruction, atopy, and eosinophilic inflammation. These patients require modified treatment approaches with greater emphasis on inhaled corticosteroids.

Some smokers show accelerated FEV₁ decline (>100 mL/year) despite similar smoking exposure, often due to genetic polymorphisms or AAT deficiency. Early recognition is important for counseling and intervention.

The diagnosis of COPD rests fundamentally on spirometry demonstrating persistent airflow obstruction. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, COPD is defined as FEV₁/FVC ratio <0.70 in a patient with relevant symptoms (dyspnea, chronic cough, sputum production) and exposure history (smoking, occupational exposures, biomass fuel). This fixed ratio is pragmatic for clinical use but recognizes that some older individuals have age-related decline in FEV₁/FVC, creating potential for overdiagnosis in the elderly.

Spirometry should be performed 15 minutes after administration of short-acting beta-2 agonist (e.g., albuterol 400 μg via metered-dose inhaler) to assess for bronchodilator response. A positive response (≥12% and ≥200 mL increase in FEV₁ or FVC) raises concern for asthma rather than COPD, though ACO exists. Lack of significant bronchodilator response supports COPD diagnosis.

Severity is classified by post-bronchodilator FEV₁ as percentage of predicted:

Recent GOLD updates (2023-2024) emphasize exacerbation history and symptoms for prognosis and treatment decisions alongside spirometry. Patients are stratified by exacerbation frequency (≥2 exacerbations or ≥1 requiring hospitalization in prior year) and symptom burden (assessed by modified Medical Research Council dyspnea scale or COPD Assessment Test).

ABG is indicated in suspected respiratory failure (dyspnea, confusion, cyanosis) or FEV₁ <25% predicted. Expected findings reflect the severity:

All COPD patients <45 years old, those with basilar/posteriorly-predominant emphysema, or rapid progression warrant AAT level testing. Values <57 μmol/L (<11 μM) or <20% of normal are considered deficient. Confirm with **PI (protease inhibitor

Surgical/definitive: lung volume reduction surgery (best in upper-lobe–predominant emphysema with low exercise capacity, per NETT), bronchoscopic endobronchial valves, and lung transplantation.

Avoid: ICS monotherapy, uncontrolled high-flow oxygen, sedatives in hypercapnia, and continued smoking. Cardioselective beta blockers are not contraindicated when cardiac indications exist.